Insys Therapeutics Inc INSY Chairman Steven Meyer and board member Pierre Lapalme will resign "upon the execution of the agreements relating to the settlement with the U.S. Department of Justice," according to Reuters.
Insys Therapeutics has agreed to pay $225 million and plead guilty to fraud to settle probes into its payment of kickbacks to induce doctors to prescribe addictive opioids. According to prosecutors, Insys used kickbacks and other illegal marketing practices to boost sales of a drug called Subsys.
The drug is extremely powerful and the risk of addiction and overdose is considered so formidable that the Food and Drug Administration requires doctors to undergo special training before they are allowed to prescribe it.
Insys shares traded higher by 28 percent to $1.11 at time of publication Thursday.
Related Links:
Insys Plunges 70% After Bankruptcy Warning
Piper Jaffray Loses Confidence In Insys Therapeutics, Downgrades Stock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
